These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 21332865)

  • 21. Use of beta-blockers in patients with an implantable cardioverter defibrillator.
    LaPointe NM; Stafford JA; Pappas PA; Al-Khatib SM; Anstrom KJ
    Ann Pharmacother; 2009 Jul; 43(7):1189-96. PubMed ID: 19567655
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ventricular tachyarrhythmias in patients receiving an implantable cardioverter-defibrillator for primary versus secondary prophylaxis indications.
    Manuchehry A; Agusala K; Montevecchi M; Kadish A; Passman R
    Pacing Clin Electrophysiol; 2011 May; 34(5):571-6. PubMed ID: 21208242
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Early Implantation of Primary Prevention Implantable Cardioverter Defibrillators for Patients with Newly Diagnosed Severe Nonischemic Cardiomyopathy.
    Voskoboinik A; Bloom J; Taylor A; Mariani J
    Pacing Clin Electrophysiol; 2016 Sep; 39(9):992-8. PubMed ID: 27343008
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Survival and appropriate device interventions in recipients of cardioverter defibrillators implanted for the primary versus secondary prevention of sudden cardiac death.
    Stockburger M; Krebs A; Nitardy A; Habedank D; Celebi O; Knaus T; Dietz R
    Pacing Clin Electrophysiol; 2009 Mar; 32 Suppl 1():S16-20. PubMed ID: 19250084
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Programming antitachycardia pacing for primary prevention in patients with implantable cardioverter defibrillators: results from the PROVE trial.
    Saeed M; Neason CG; Razavi M; Chandiramani S; Alonso J; Natarajan S; Ip JH; Peress DF; Ramadas S; Massumi A
    J Cardiovasc Electrophysiol; 2010 Dec; 21(12):1349-54. PubMed ID: 20561107
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Implantable cardioverter-defibrillators in hypertrophic cardiomyopathy.
    Vieira AP; Adragão PP; Santos KR; Morgado FB; Cavaco DM; Rossi R; Abecasis M; Neves JP; Bonhosrst D; Gomes JL; Gomes RS
    Rev Port Cardiol; 2005 Mar; 24(3):407-15. PubMed ID: 15929624
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Implantable cardioverter defibrillator therapy for prevention of sudden cardiac death in children in the Netherlands.
    Heersche JH; Blom NA; van de Heuvel F; Blank C; Reimer AG; Clur SA; Witsenburg M; ten Harkel AD
    Pacing Clin Electrophysiol; 2010 Feb; 33(2):179-85. PubMed ID: 20025697
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Myocardial fibrosis predicts appropriate device therapy in patients with implantable cardioverter-defibrillators for primary prevention of sudden cardiac death.
    Iles L; Pfluger H; Lefkovits L; Butler MJ; Kistler PM; Kaye DM; Taylor AJ
    J Am Coll Cardiol; 2011 Feb; 57(7):821-8. PubMed ID: 21310318
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Death without prior appropriate implantable cardioverter-defibrillator therapy: a competing risk study.
    Koller MT; Schaer B; Wolbers M; Sticherling C; Bucher HC; Osswald S
    Circulation; 2008 Apr; 117(15):1918-26. PubMed ID: 18391108
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of transvenous implantable cardioverter-defibrillators in preventing sudden cardiac death in children, adolescents, and young adults.
    Chatrath R; Porter CB; Ackerman MJ
    Mayo Clin Proc; 2002 Mar; 77(3):226-31. PubMed ID: 11888025
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term follow-up of primary and secondary prevention implantable cardioverter defibrillator patients.
    van Welsenes GH; van Rees JB; Borleffs CJ; Cannegieter SC; Bax JJ; van Erven L; Schalij MJ
    Europace; 2011 Mar; 13(3):389-94. PubMed ID: 21208947
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Are implantable cardioverter defibrillator shocks a surrogate for sudden cardiac death in patients with nonischemic cardiomyopathy?
    Ellenbogen KA; Levine JH; Berger RD; Daubert JP; Winters SL; Greenstein E; Shalaby A; Schaechter A; Subacius H; Kadish A;
    Circulation; 2006 Feb; 113(6):776-82. PubMed ID: 16461817
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of age and medical comorbidity on the effectiveness of implantable cardioverter-defibrillators for primary prevention.
    Chan PS; Nallamothu BK; Spertus JA; Masoudi FA; Bartone C; Kereiakes DJ; Chow T
    Circ Cardiovasc Qual Outcomes; 2009 Jan; 2(1):16-24. PubMed ID: 20031808
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effectiveness of implantable defibrillators in octogenarians and nonagenarians for primary prevention of sudden cardiac death.
    Mezu U; Adelstein E; Jain S; Saba S
    Am J Cardiol; 2011 Sep; 108(5):718-22. PubMed ID: 21640321
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy.
    Maron BJ; Shen WK; Link MS; Epstein AE; Almquist AK; Daubert JP; Bardy GH; Favale S; Rea RF; Boriani G; Estes NA; Spirito P
    N Engl J Med; 2000 Feb; 342(6):365-73. PubMed ID: 10666426
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Deactivation of implantable cardioverter-defibrillators: results of patient surveys.
    Herman D; Stros P; Curila K; Kebza V; Osmancik P
    Europace; 2013 Jul; 15(7):963-9. PubMed ID: 23447573
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Implantable cardioverter-defibrillators in the prevention of sudden cardiac death].
    Kozák M; Krivan L; Semrád B
    Vnitr Lek; 2001 Jun; 47(6):361-70. PubMed ID: 11494881
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differences in tachyarrhythmia detection and implantable cardioverter defibrillator therapy by primary or secondary prevention indication in cardiac resynchronization therapy patients.
    Wilkoff BL; Hess M; Young J; Abraham WT
    J Cardiovasc Electrophysiol; 2004 Sep; 15(9):1002-9. PubMed ID: 15363071
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Implantable cardioverter defibrillators and quality of life: results from the defibrillators in nonischemic cardiomyopathy treatment evaluation study.
    Passman R; Subacius H; Ruo B; Schaechter A; Howard A; Sears SF; Kadish A
    Arch Intern Med; 2007 Nov; 167(20):2226-32. PubMed ID: 17998496
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term follow-up on high-rate cut-off programming for implantable cardioverter defibrillators in primary prevention patients with left ventricular systolic dysfunction.
    Clementy N; Pierre B; Lallemand B; Marie O; Lemoine E; Cosnay P; Fauchier L; Babuty D
    Europace; 2012 Jul; 14(7):968-74. PubMed ID: 22389416
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.